The thyroid hormone (TH) analog eprotirome (KB2115) was developed to lower cholesterol through selective activation of the TH receptor (TR) b1 in the liver. Interestingly, eprotirome shows low uptake in nonhepatic tissues, explaining its lipid-lowering action without adverse extrahepatic thyromimetic effects. Clinical trials have shown marked decreases in serum cholesterol levels. We explored the transport of eprotirome across the plasma membrane by members of three TH transporter families: monocarboxylate transporters MCT8 and MCT10; Na-independent organic anion transporters 1A2, 1B1, 1B3, 1C1, 2A1, and 2B1; and Na-dependent organic anion transporters SLC10A1 to SLC10A7. Cellular transport was studied in transfected COS1 cells using [ Of the 15 transporters tested initially, the liver-specific bile acid transporter SLC10A1 showed the highest eprotirome uptake (greater than a sevenfold induction after 60 minutes) as well as TRb1-mediated transcriptional activity. Uptake of eprotirome by SLC10A1 was Na + dependent and saturable with a Michaelis constant of 8 mM. Eprotirome transport was inhibited by known substrates for SLC10A1 (e.g., cholate and taurocholate), and by TH analogs such as triiodothyropropionic acid and triiodothyroacetic acid. However, no significant SLC10A1-mediated transport was observed of these [ 125 I]TH analogs. We also studied the plasma disappearance and biliary excretion of [ 14 C]eprotirome injected in control and Slc10a1 knockout mice. Although eprotirome is also transported by mouse Slc10a1, the pharmacokinetics of eprotirome were not affected by Slc10a1 deficiency. In conclusion, we have demonstrated that the liver-specific bile acid transporter SLC10A1 effectively transports eprotirome. However, Slc10a1 does not appear to be critical for the liver targeting of this TH analog in mice. Therefore, the importance of SLC10A1 for liver uptake of eprotirome in humans remains to be elucidated. (Endocrinology 158: 3307-3318, 2017) 
I]TH analogs. Of the 15 transporters tested initially, the liver-specific bile acid transporter SLC10A1 showed the highest eprotirome uptake (greater than a sevenfold induction after 60 minutes) as well as TRb1-mediated transcriptional activity. Uptake of eprotirome by SLC10A1 was Na + dependent and saturable with a Michaelis constant of 8 mM. Eprotirome transport was inhibited by known substrates for SLC10A1 (e.g., cholate and taurocholate), and by TH analogs such as triiodothyropropionic acid and triiodothyroacetic acid. However, no significant SLC10A1-mediated transport was observed of these [ 125 I]TH analogs. We also studied the plasma disappearance and biliary excretion of [ 14 C]eprotirome injected in control and Slc10a1 knockout mice. Although eprotirome is also transported by mouse Slc10a1, the pharmacokinetics of eprotirome were not affected by Slc10a1 deficiency. In conclusion, we have demonstrated that the liver-specific bile acid transporter SLC10A1 effectively transports eprotirome. However, Slc10a1 does not appear to be critical for the liver targeting of this TH analog in mice. Therefore, the importance of SLC10A1 for liver uptake of eprotirome in humans remains to be elucidated. (Endocrinology 158: 3307-3318, 2017) H ypercholesterolemia is associated with atherosclerosis and thus represents a major health risk for ischemic heart disease and stroke, the foremost causes of death in middle-and high-income countries (1) . Thyroid hormone (TH) plays an important role in the regulation of different steps in lipid metabolism such as lipolysis and hepatic cholesterol clearance (2) . These effects are importantly mediated by the stimulation of thyroid hormone receptor (TR) b1 (TRb1) in the liver by triiodothyronine (T3) (2) . Therefore, reduction of serum cholesterol by TRb-selective TH analogs without adverse thyromimetic effects has obvious therapeutic benefits. The TRb specificity of such analogs would indeed prevent unwanted cardiovascular effects of TH analogs mediated by TRa1. However, it would not prevent the suppression of the hypothalamus-pituitary-thyroid axis by such analogs via the TRb2 receptor expressed in hypothalamus and pituitary. TH receptors are located in the nucleus and the action of T3 and analogs requires their cellular uptake by plasma membrane transporters. This makes it possible to target lipid-lowering TH analogs to the liver through liverspecific transporters.
One of the TH analogs developed to lower cholesterol is eprotirome (KB2115; 3-[ [3,5-dibromo-4 -[4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic acid) (3) . It differs from T3 by the presence of two bromines instead of iodine substituents in the inner ring, an isopropyl group instead of an iodine substituent in the outer ring, and a 3-amino-3-oxopropionic acid instead of an alanine side chain (Supplemental Fig. 1 ). It has two characteristics that make it an attractive candidate as a lipid-lowering drug: (1) modestly higher affinity for TRb than for TRa and (2) minimal nonhepatic tissue uptake. Interestingly, recent rodent studies demonstrated reduction of cholesterol by T3 and eprotirome through a low-density lipoprotein receptor independent pathway (4), indicating a mechanism distinct from other lipid-lowering agents. In a 12-week clinical trial in which the TH analog was given in addition to statin therapy, eprotirome produced a marked decrease in serum cholesterol levels without adverse extrahepatic thyromimetic effects (3). However, phase III clinical trials were discontinued because long-term studies in dogs resulted in cartilage damage (5) .
It is important to gain insight in eprotirome's mechanism of action and its pronounced liver-selective uptake for future development of lipid-lowering TH analogs. As mentioned above, TH action is dependent on cellular uptake by plasma membrane transporters, which may also apply to TH analogs. Therefore, the objective of our study was to get a better understanding of the tissue-specific actions of eprotirome by exploring the role of TH transporters in tissue uptake of eprotirome. Because of the presence of a negatively charged side chain in eprotirome, we focused primarily on the possible involvement of organic anion transporters. Different (Na-independent) organic anion transporting polypeptides (OATPs), as well as Na/taurocholate cotransporting polypeptide (NTCP; SLC10A1), are capable of transporting TH (6) (7) (8) . Therefore, we concentrated on the OATP and SLC10 families in our search for transporters facilitating cellular uptake of eprotirome. For comparison, we also tested possible eprotirome transport by MCT8 (SLC16A2) and MCT10 (SLC16A10), the most effective TH transporters identified to date (9) . 0 ,5,5 0 -tetraiodothyroacetic acid (Tetrac; TA4) were produced as previously described (10) .
Materials and Methods

Materials
Plasmids
Human (h) OATP1A2 in pSPORT1 was kindly provided by Prof. Dr. Peter J. Meier (Institute of Clinical Pharmacology and Toxicology, University Hospital Zürich, Zürich, Switzerland), and subcloned into pSG5 (Stratagene, La Jolla, CA). hOATP1B3 in pcDNA3.1-Hygro was kindly provided by Prof. Dr. Dietrich Keppler (German Cancer Research Center, Heidelberg, Germany), and subcloned into pSG5. hOATP1B1 in pCMV6-XL4 (11); hOATP1C1 in pcDNA3.1 (12); hSLC10A1, hSLC10A2, and hSLC10A3 in pcDNA3; rat Slc10a4, hSLC10A5, hSLC10A6, and hSLC10A7 in pcDNA5 (7); hMCT8 in pcDNA3 (13) ; and hMCT10 in pcDNA3.1 (14) were obtained as described previously. hOATP2A1 and hOATP2B1 in pCMV. SPORT6 were purchased from Open Biosystems (Huntsville, AL). hSLC10A1 and mSlc10a1 were subcloned into pSG5 with a 5 0 -FLAG tag and an optimized Kozak sequence as previously described (15) .
Cell culture and transfection
Most transport assays were done using transfected COS1 (African green monkey kidney) cells, but some experiments were also done with JEG3 (human choriocarcinoma) cells. Cells were maintained in culture medium (DMEM/F12+glutamax, 9% fetal bovine serum, 1% penicillin/streptomycin, 100 nM Na 2 SeO 3 ) at 37°C and 5% CO 2 . Cells were seeded in six-well or 24-well culture dishes in culture medium without antibiotics. At 70% confluence, cells were transfected with 200-ng (24-well dishes) or 500-ng (six-well dishes) transporter plasmid or empty vector using X-tremeGENE 9 transfection reagent in a 3:1 ratio, according to the manufacturer's protocol.
Transport studies
Time-dependent uptake assays were done in six-well dishes. All other transport studies were performed in 24-well dishes, producing similar results as in six-well dishes. Experiments were carried out 48 hours after transfection. Cells were rinsed with incubation medium (Dulbecco's phosphate buffered saline/ 0.1% BSA/0.1% D-glucose or DMEM/F12-GlutaMAX with 0.1% BSA) and incubated for 2 to 60 minutes at 37°C and 5% CO 2 with 0.5 mM (6 3 10 4 or 12 3 10 4 cpm) [ 14 C]eprotirome in 0.5 or 1 mL incubation medium in 24-well or six-well dishes, respectively. After incubation, cells were rinsed with incubation medium, lysed in 0.5 mL 0.1 M NaOH, mixed with 4 mL scintillation fluid (Pico-Fluor 15, Perkin-Elmer), and counted for radioactivity in a b-counter (Perkin-Elmer , and cellular radioactivity was measured as described earlier using a g counter (16) . 
Effect of liver transporters on nuclear activity of eprotirome
To explore the effect of SLC10A1 on the nuclear availability of eprotirome, we used a TRb1-dependent transactivation assay as described previously with minor modifications (17) . COS1 and JEG3 cells were cultured in 96-well plates, and cotransfected with 15 ng pcDNA3.1-hTRb1, 15 ng of the pdV-L1 plasmid containing a T3 response element-dependent firefly luciferase reporter and a control renilla luciferase reporter (18) , and 15 ng pcDNA3-SLC10A1 or empty pcDNA3 vector. Two days after transfection, cells were incubated for 24 hours with 0, 0.1, or 1 nM eprotirome in DMEM/F12-GlutaMAX containing 0.1% BSA. Firefly luciferase and renilla luciferase activities were determined using the Dual-Glo Luciferase Assay (Promega, Leiden, The Netherlands), and the luciferase/renilla ratio was calculated as a readout for eprotirome transcriptional activity.
Quantitative reverse transcription polymerase chain reaction of tissue SLC10A1 mRNA levels
Complementary DNA prepared from human liver, cartilage, bone marrow, sternum, and chondrosarcoma was kindly provided by Dr. Bram van der Eerden (Erasmus University Medical Center, Rotterdam, The Netherlands). SLC10A1 quantitative polymerase chain reaction was carried out using 5 0 -GGTTCTCATTCCTTGCACCA-3 0 as the forward primer, 5 0 -ATGGCAGAGAGAACTGTGACG-3 0 as the reverse primer, SYBRgreen as the probe, and universal master mix (Roche). SLC10A1 expression levels were expressed relative to the expression of the HPRT1 housekeeping gene measured using a commercial primer-probe mix (Applied Biosystems, Nieuwerkerk aan den IJssel, The Netherlands).
Immunoblotting
Expression of FLAG-hSLC10A1 and FLAG-mSlc10a1 protein in COS1 cells was determined by immunoblotting using anti-FLAG antibody as previously described (19) . In brief, transfected COS1 cells were lysed in ice-cold radioimmunoprecipitation assay buffer supplemented with the Complete Protease Inhibitor cocktail (Roche Diagnostics). Lysates were cleared by centrifugation for 5 minutes at 700 3 g, and protein concentration of the supernatant was determined using the bicinchoninic assay (Thermo Fisher Scientific, Waltham, MA). Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes, which were blocked in Tris-buffered saline with Tween/5% milk and probed overnight with a 1:1000 dilution of mouse FLAG M2-antibody (F1804; Sigma-Aldrich) at 4°C. Bound antibody was detected with a horseradish peroxidase-conjugated goat anti-mouse antibody (#172-1011; Bio-Rad, Veenendaal, The Netherlands) and visualized by enhanced chemiluminescence using the Alliance 4.0 Uvitec platform (Uvitec Ltd., Cambridge, UK).
Eprotirome pharmacokinetics in wild-type and Slc10a1 deficient mice
Male Slc10a1 knockout mice (C57Bl6/J background), and wild-type or heterozygous littermates were housed and bred in the Academic Medical Center in Amsterdam. As heterozygote littermates have almost 90% of normal NTCP expression and indistinguishable from wild-type (20) , these were used as control.
To investigate eprotirome transport in control and Slc10a1 knockout mice, the gall bladder was cannulated and bile was collected after distal ligation of the common bile duct, as described (21) . After a 30-minute depletion phase, a single bolus of 14 C-labeled eprotirome was administered intravenously in 100 mL 0.9% NaCl per 20-g mouse. Blood and bile samples were collected at the indicated time points after eprotirome administration. Mice were euthanized, and liver, kidney, heart, and brain were dissolved in Solvable (Perkin Elmer). Radioactivity in plasma and bile was measured by liquid scintillation counting. Total blood volume was estimated based on the mouse body weight (58.5-mL/g mouse).
Statistical analysis
The results are shown as means 6 standard error of the mean of usually three experiments carried out at least in duplicate. GraphPad Prism 5.01 was used for statistical analysis. To test the significance of the difference between background and transporter-mediated eprotirome uptake, a one-way analysis of variance with Bonferroni posttest was used. A paired t test was used to test the difference in uptake of different substrates between cells transfected with empty vector or with SLC10A1. P , 0.05 was considered significant.
Results
In addition to the TH transporters MCT8 and MCT10, six members of the OATP family and all seven members of the SLC10 family were tested for [ 14 C]eprotirome uptake in transfected COS1 cells (Fig. 1A) . Of all 18 transporters tested, SLC10A1 showed a robust increase in eprotirome uptake compared with empty vector. OATP1A2, OATP1B1, OATP1B3, SLC10A6, and SLC10A7 produced a modest, insignificant increase in eprotirome uptake. Figure 1B shows a strong time-dependent increase in eprotirome uptake by COS1 cells transfected with SLC10A1, whereas no increase in eprotirome uptake with time was observed in cells transfected with empty vector. The latter suggests that COS1 cells do not express endogenous transporters for eprotirome. The fold stimulation of eprotirome uptake induced by SLC10A1 vs. empty vector increased from 1.4 at 2 minutes to 7.1 at 60 minutes. Even after 24 hours, a 4.6-fold induction in eprotirome uptake was seen in COS1 cells expressing SLC10A1 (Fig. 1C) . In contrast to COS1 cells, control JEG3 cells showed a significant time-dependent uptake of eprotirome, representing expression of endogenous transporter(s) that facilitate eprotirome uptake (Fig. 1D) . Transfection of JEG3 cells with SLC10A1 produced a time-dependent increase in eprotirome uptake up to 1.7-fold at 60 minutes. However, no marked induction of eprotirome uptake by SLC10A1 was found anymore after 24 hours in JEG3 cells (Fig. 1C) .
SLC10A1 (NTCP) transports its substrates in a Na + -dependent manner (6, 22) . To assess if eprotirome transport by SLC10A1 is also a Na + -dependent process, parallel incubations were carried out with Na + replete medium or with Na + deplete medium where all Na + was replaced by choline. In both COS1 and JEG3 cells, eprotirome transport by SLC10A1 was found to be strictly dependent on the presence of Na + in the medium ( Fig. 2A) . Interestingly, eprotirome uptake by control JEG3 cells was not affected by Na + depletion, indicating the involvement of Na + -independent endogenous transporter(s) and thus distinct from SLC10A1. Because of the considerable endogenous uptake by JEG3 cells, further transport characteristics of eprotirome by SLC10A1 were investigated using COS1 cells.
Next, we examined if, in addition to eprotirome uptake, SLC10A1 also facilitates eprotirome efflux. COS1 cells were loaded during incubation for 30 findings that Na + depletion and cholate do not inhibit eprotirome efflux suggest that this is not mediated by SLC10A1, although efflux from cells transfected with empty vector followed different kinetics. The uptake of eprotirome by control cells is much lower than the uptake in SLC10A1-transfected cells and plateaus after a very short incubation time (;10 minutes). It cannot be excluded that a part of the eprotirome is associated with but not internalized by the control cells, which then shows a rapid dissociation from the cells. Na + depletion and cholate also did not affect efflux of eprotirome from control cells. The kinetics of eprotirome transport by SLC10A1 were studied by incubation of transfected cells with 0.5 to 200 mM eprotirome, and subtraction of eprotirome uptake by control cells from uptake by SLC10A1-expressing cells. The results clearly demonstrate saturation of eprotirome transport by SLC10A1 (Fig. 3) . Based on these data, a Km value of approximately 10 mM was estimated.
We examined if SLC10A1 increases the nuclear availability of eprotirome using COS1 and JEG3 cells cotransfected with TRb1 and a construct coding for a T3 response element-dependent luciferase reporter and a control renilla reporter. The luciferase/renilla ratio was used as a measure of the transcriptional activity of eprotirome. In the absence of SLC10A1, 0.1 nM eprotirome was inactive, whereas 1 nM eprotirome induced a modest increase in transcriptional activity (Fig. 4A) . In contrast, a marked, dose-dependent transcriptional activity was observed in JEG3 cells (Fig. 4B) . Expression of SLC10A1 resulted in a 5.7-and 4.3-fold increase in transcriptional activity in COS1 cells exposed to 0.1 and 1 nM https://academic.oup.com/endoeprotirome, respectively. In JEG3 cells, SLC10A1 expression enhanced transcriptional activity of 0.1 nM but not of 1 nM eprotirome, where the latter already shows maximum activity in the absence of SLC10A1. As SLC10A1 also mediates transport of bile acids, steroid sulfates and cholephilic compounds such as BSP (6, 7, 22) , we studied the inhibitory effects of 50 mM taurocholate, cholate, DHEAS, E3S, and BSP on eprotirome transport by SLC10A1 (Fig. 5A) . Eprotirome transport was inhibited in decreasing order of potency by taurocholate ; cholate . BSP ; E3S . DHEAS.
The preceding experiments indicate that eprotirome is an excellent substrate for the organic anion transporter SLC10A1. Therefore, we investigated if other TH analogs with a negatively charged side chains could also be substrates for SLC10A1. This was studied indirectly by measuring the effects of TA4, TA3, TP3 and DP2 on eprotirome uptake by SLC10A1 in comparison with the effects of T4 and T3. As expected, minimal effects on eprotirome uptake were seen by addition of 50 mM T3 or T4 (Fig. 5B) . However, eprotirome uptake was markedly inhibited in decreasing order of potency by 50 mM TP3 . TA3 . TA4 . DP2. Dose-dependent inhibition of eprotirome uptake by SLC10A1 in the presence of increasing concentrations of TA4, TA3, TP3 and DP2 is presented in Supplemental Fig. 2 , indicating nearcomplete inhibition at the highest concentration of the analogs tested (100 mM).
To explore if the TH analogs were also substrates for SLC10A1, transport was directly measured in transfected COS1 cells using [ 125 I]T3 (Fig. 6A) Fig. 3 ). These findings indicate that SLC10A1 is not involved in the possible targeting of eprotirome to human cartilage.
Our findings suggest that SLC10A1 is an important transporter for hepatic uptake of eprotirome. To test this hypothesis, we studied the pharmacokinetics of eprotirome in Slc10a1 knockout mice and control littermates (20) , assuming that eprotirome is also effectively transported by mouse Slc10a1. To compare the expression and activity of mouse and human SLC10A1, COS1 cells were transfected with FLAG-tagged constructs and tested for protein expression by immunoblotting using anti-FLAG antibody and for eprotirome uptake.
Protein expression levels ( Fig. 7A ) and cellular uptake of taurocholate and eprotirome (Fig. 7B) were somewhat lower for FLAG-tagged mouse Slc10a1 than for the human SLC10A1 construct. Surprisingly, plasma clearance and biliary excretion of injected [
14 C]eprotirome were not significantly different between control and Slc10a1 knockout mice (Fig. 7C) . However, we noted a strong sex dependence of the data obtained, indicating that both plasma clearance and biliary excretion of eprotirome were markedly higher in male than in female mice irrespective of Slc10a1 status (Fig. 7D) . The amount of eprotirome present at the end of the experiment was markedly higher in liver than in kidney, heart, and brain ( Fig. 7C and 7D ). However, there was no significant difference between the amounts of eprotirome finally present in the tissues comparing male with female mice or Slc10a1 knockout with control mice.
Discussion
This study shows that transporters are required for transport of eprotirome across the plasma membrane, a necessary step to enable its activation of nuclear T3 receptors. We also demonstrate that eprotirome is effectively transported into cells by the liver-specific transporter SLC10A1. However, the importance of SLC10A1 for the liver targeting of eprotirome in humans remains to be determined.
Because an intact alanine side chain is required for effective transport of iodothyronines by MCT8 and MCT10 (23, 24) , it is not surprising that eprotirome is not transported by these TH transporters. In view of the negatively charged side chain of eprotirome, we hypothesized that cellular uptake of this TH analog is facilitated by an organic anion transporter. We showed that of the 13 organic anion transporters tested in our first experiments, the bile acid transporter SLC10A1 markedly stimulated cellular uptake of eprotirome. SLC10A1 is known to transport bile acids, steroid sulfates (22) , and iodothyronine sulfates (6, 7) in a Na + -dependent manner. This was also found to be the case for eprotirome uptake by SLC10A1, because this was completely blocked under Na + deplete conditions. Consistent with previous findings of the unidirectional transport of other substrates (7), SLC10A1 does not appear to mediate cellular efflux of eprotirome.
Experiments using control COS1 cells transfected with empty vector indicate that very little if any eprotirome is taken up by cells through simple diffusion across the plasma membrane. The amount of radioactive eprotirome associated with control COS1 cells does not increase with time after 2 minutes, suggesting that this largely represents binding of eprotirome to the cell surface. This may also explain the rapid release of labeled eprotirome from control COS1 cells in the efflux experiments. The negligible endogenous uptake of eprotirome by COS1 cells permits their use to study the characteristics of eprotirome transport by SLC10A1. Considering the lack of eprotirome transport into control COS1 cells, the sevenfold increase in cell-associated eprotirome after 30 minutes of incubation with SLC10A1-transfected cells represents an underestimation of the increase in cellular uptake induced by SLC10A1. These findings indicate that eprotirome is effectively transported by SLC10A1, which is further supported by the marked stimulation of the TRmediated action of eprotirome induced by this transporter. This confirms that cellular uptake of eprotirome by SLC10A1 also results in a prominent increase in the nuclear availability of this T3 analog.
SLC10A1 has a relatively high affinity for eprotirome with an apparent Km value of 7.8 mM, compared with Km values reported for other substrates such as taurocholate (6 to 34 mM), E3S (27 to 60 mM) and BSP (3.7 mM) (22) . As expected, transport of eprotirome by SLC10A1 is inhibited by the alternative substrates cholate, taurocholate, E3S, DHEAS, and BSP, suggesting that they compete for the same translocation pathway in SLC10A1. The strongest competition was observed with the bile acids cholate and taurocholate. Obviously, the presence of a negative charge in the substrate is important for its transport by SLC10A1. This is also the case for sulfonated T4 and T3 derivatives (sulfates and sulfamates), which appear to be transported better by SLC10A1 than T4 and T3 themselves (6, 7) . The presence of the negatively charged 3-amino-3-oxopropionic acid side chain of eprotirome probably contributes importantly to the effective transport of this T3 analog by SLC10A1. For this reason, we also expected that other iodothyronine derivatives with an anionic side chain, such as TA4, TA3, TP3, and TP2, are also effectively transported by SLC10A1. Although these compounds strongly inhibit eprotirome transport by SLC10A1, studies using 125 I-labeled TA4, TA3, and TP3 failed to demonstrate significant transport by SLC10A1. T4 and T3 are poor inhibitors of eprotirome transport by SLC10A1, while they are also poorly transported by SLC10A1. In agreement with previous studies (7), T4 showed minimal uptake by SLC10A1, whereas T3 transport was undetectable. This difference in transport between T4 and T3 may be explained by the presence of a negative charge due to dissociation of the phenolic hydroxyl group of T4 at neutral pH and the absence of such charge on T3. The observation that iodothyronine derivatives with anionic side chains (e.g., TA3, TP3) are potent inhibitors but poor substrates for SLC10A1 in contrast to eprotirome may suggest that the presence of larger iodine vs. bromine and isopropyl substituents interferes with the passage of substrate through SLC10A1.
Our studies in mice confirm that eprotirome is largely targeted to the liver. Despite the effective transport of eprotirome by both human and mouse SLC10A1 in transfected cells, its plasma disappearance and biliary clearance were not distinctly different between WT and Slc10a1 knockout mice. Instead, a marked influence of sex was observed, as both plasma disappearance and biliary clearance of eprotirome were markedly higher in male than in female mice. These differences are most likely explained by a more rapid hepatic uptake of eprotirome in male vs female mice, although the liver eprotirome content at the end of the experiment was not obviously different between males and females.
Many hepatic genes are expressed sex dependently in mice, including the liver-specific transporters Oatp1a1 and 1a4. Oatp1a1 is expressed at higher levels in male mice, whereas Oatp1a4 shows higher expression in female mice (25) . The expression of another liver-specific transporter, Oatp1b2, is not clearly sex-dependent (26) . Therefore, Oatp1a1 may also be an important transporter for liver uptake of eprotirome. We were unable to test this hypothesis as we failed to obtain functional expression of Oatp1a1 in transfected mammalian cells. This may be due to the absence of proteins required for expression of Oatp1a1-dependent transport activity, such as Atp11c, Cdc50a, Pdzk1, and perhaps other factors (27, 28) . This may also apply to our findings of a low uptake of eprotirome by human OATP1B1 and 1B3, although we previously demonstrated significant transport activity using other substrates (11, 29) . We are now exploring optimal conditions for functional expression of OATP1B1 and 1B3, and preliminary results show that this is cell-dependent.
Finally, the lack of an obvious defect in liver eprotirome uptake in Slc10a1 deficient mice may be due to increased expression of other transporters. However, expression of Oatp1a1 and 1b2 is not increased in Slc10a1 knockout mice, while expression of Oatp1a4 is only increased in hypercholanemic Slc10a1 knockout mice (20) .
The small decrease in serum T4 combined with unaffected TSH levels in patients treated with eprotirome suggests some extrahepatic activity (3, 30) . The modest decrease in T4 may be explained by an increase in liver D1 activity, and the lack of an increase in TSH may represent a modest activity of eprotirome at the hypothalamus and/or pituitary (3).
MCT8 is known to be widely expressed in cartilageforming chondrocytes, whereas MCT10 appears to be the preferentially expressed transporter in the growth plate (31) . However, these two transporters do not show any eprotirome uptake. The lack of expression of SLC10A1 in human cartilage does not exclude that eprotirome is targeted to cartilage through another transporter, producing the unwanted side effects of eprotirome on this tissue as observed in longterm studies in dogs. Our studies in human cartilage also do not negate that SLC10A1 may be expressed in dog cartilage. More studies are required to resolve this issue.
Finally, clinical studies with eprotirome indicate good oral availability of this T3 analog (3), indicating the presence of transporters for eprotirome in the intestinal mucosa. Our studies demonstrate that the SLC10A2 intestinal bile acid transporter is not involved in the absorption of oral eprotirome.
SLC10A1 transports a broad range of substrates, in particular bile acids (22, 32) , that may interfere with hepatic eprotirome uptake in vivo. In addition to physiological substrates, certain drugs may also be transported by SLC10A1, and thus also interfere with eprotirome uptake. Recent studies have indicated that uptake of statins into the liver is partly mediated by SLC10A1 (33) (34) (35) (36) . This is of particular interest because statins and eprotirome have the same therapeutic goal, that is, reduction of serum cholesterol. A recent clinical trial has indicated that the combined therapy with statins and eprotirome produces a greater reduction in serum cholesterol than treatment with statins alone (3) . Despite this positive clinical outcome, our results suggest that the effectiveness of combined TH analog and statin therapy may be limited by drug-drug interaction at the level of hepatic transport.
In conclusion, the liver-specific bile acid transporter SLC10A1 effectively transports eprotirome into cells. The high expression of this transporter in liver may explain the liver-selective action of this TH analog. However, hepatic eprotirome uptake is not affected in Slc10a1 knockout mice, suggesting an important contribution of other liver-specific transporters. Our findings support the hypothesis that TH analogs may be targeted to specific tissues depending on the transporters they express.
